Difference between revisions of "Prostate cancer with neuroendocrine differentiation"

From Libre Pathology
Jump to navigation Jump to search
(split out)
(No difference)

Revision as of 16:29, 19 March 2018

Neuroendocrine carcinoma of the prostate is a rare group of prostate cancers that is hypothesized to evolve in the context androgen deprivation therapy.[1]

It is subclassified as per Epstein et al.:[1]

  • Usual prostate adenocarcinoma with neuroendocrine differentiation.
  • Adenocarcinoma with Paneth cell neuroendocrine differentiation.
  • Carcinoid tumour of the prostate.
  • Small cell carcinoma of the prostate gland.
  • Large cell neuroendocrine carcinoma of the prostate.
  • Mixed (small and/or large cell) neuroendocrine carcinoma-acinar adenocarcinoma.

IHC

  • PSA typically negative in NE carcinoma.

See also

References

  1. ↑ 1.0 1.1 Epstein, JI.; Amin, MB.; Beltran, H.; Lotan, TL.; Mosquera, JM.; Reuter, VE.; Robinson, BD.; Troncoso, P. et al. (Jun 2014). "Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.". Am J Surg Pathol 38 (6): 756-67. doi:10.1097/PAS.0000000000000208. PMID 24705311.
Retrieved from "https://librepathology.org/w/index.php?title=Prostate_cancer_with_neuroendocrine_differentiation&oldid=48790"